NatureMedical has discontinued distribution of Pomi-T in the UK following new clinical research by the original study group showing stronger biomarker effects with a newer phytochemical formulation, now marketed as YourPhyto.
The decision follows a larger, more recent trial led by Professor Robert Thomas and researchers from Cambridge University Hospitals, in collaboration with teams in the US and Australia.
The study evaluated a new blend of phytochemical-rich foods, now marketed as YourPhyto, rather than the original Pomi-T formulation.
According to NatureMedical, the scientific committee reported significant effects on cancer-related biomarkers, alongside improvements in markers of inflammation, strength and urinary symptoms.
The findings were presented at the ASCO Genitourinary Cancers Symposium in San Francisco and published in the journal European Urology Oncology in October 2025.
Pomi-T was originally developed based on research conducted approximately 14 years ago.
NatureMedical has said that, in light of the newer data and improved outcomes reported with the updated formulation, it no longer feels able to endorse or support the distribution of Pomi-T in the UK.
No safety concerns have been raised in relation to Pomi-T and the company has not indicated that the product has been withdrawn for regulatory reasons.